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SIRT6 is a member of the sirtuin family of class III histone deacetylases. It plays important roles in
regulating genomic stability, metabolism, stress response and aging. Our previous study has revealed
that SIRT6 attenuates myocardial hypertrophy by inhibiting NF-kB activation, but the related molecular
mechanisms remain to be clariﬁed. In the present study, we showed that the p300 acetylase was
involved in the protective effect of SIRT6 against phenylephrine (PE)-induced cardiomyocyte hypertro-
phy. In cultured neonatal rat cardiomyocytes, the expression and activity of SIRT6 declined following PE
treatment, while the protein level of p300 was upregulated. PE triggered signiﬁcant hypertrophic re-
sponses as manifested by increase in cellular surface area and expression of hypertrophy marker genes,
which could be blocked by SIRT6 overexpression. Mechanistically, SIRT6 reduced p300 protein expres-
sion via promoting its degradation, which could be attributed to the suppression of PI3K/Akt signaling.
The downregulation of p300 protein level by SIRT6 subsequently decreased the acetylation and tran-
scriptional activity of NF-kB p65 subunit. These ﬁndings help to further understand mechanisms un-
derlying the anti-hypertrophic role of SIRT6 and suggest the potential of SIRT6 as a therapeutic target for
cardiac hypertrophy.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
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d/4.0/).enlargement of cardiomyocyte size, reactivation of fetal genes,
and reorganization of cytoskeleton (1, 2). It initially helps to
normalize wall stress and preserve systolic function, but sustained
hypertrophy will eventually result in a decompensatory phase
with deleterious consequences (3, 4). As a common pathological
feature of some major cardiovascular diseases including hyper-
tension and myocardial infarction, cardiac hypertrophy is strongly
associated with a high risk of heart failure and sudden death (5, 6).
During the last decades, extensive efforts have been made to
understand the pathogenesis and progress of cardiac hypertrophy.
Unfortunately, its underlying molecular mechanisms remain to be
elucidated.
The sirtuin family proteins are evolutionarily conserved nicotine
adenine dinucleotide (NAD)-dependent class III histone deacety-
lases (HDACs) that play predominant roles in controlling critical
cellular processes such as differentiation, proliferation, apoptosis,nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
P. Shen et al. / Journal of Pharmacological Sciences 132 (2016) 31e4032metabolism and aging (7, 8). The malfunction of sirtuins is known
to promote a variety of human diseases such as diabetes, inﬂam-
mation, cancer and neurodegenerative disease (9). During recent
years, the roles of sirtuin family in cardiovascular system have
attracted increasing attentions. Inmammals, there are seven sirtuin
isoforms named SIRT1-7. Among them, SIRT1, SIRT3 and SIRT7 have
been demonstrated to be intensively involved in pathological car-
diac growth (10e12). Nucleus-localized SIRT6 is also an important
sirtuin isoform with numerous cellular functions (13). SIRT6 pro-
tein expression declines in failing human and hypertrophic mouse
hearts. Mice with cardiac-speciﬁc knockout of SIRT6 spontaneously
develop cardiac hypertrophy and heart failure, whereas transgenic
overexpression of SIRT6 in the heart blocks pressure overload and
agonist-induced hypertrophy (14). Thus, SIRT6 has been suggested
to be a negative regulator of cardiac hypertrophy.
The anti-hypertrophic effect of SIRT6 can be attributed to its
inhibition of insulin-like growth factor (IGF)-Akt signaling-related
genes expression, via interacting with c-Jun and deacetylating
histone H3 lysine 9 (H3K9) (14). Recently, the studies by our group
and other researchers also revealed that the suppression of nuclear
factor kappa B (NF-kB) signaling contributes to the protective role
of SIRT6 (15, 16). SIRT6 attenuated cardiomyocytes hypertrophy by
suppressing NF-kB-dependent transcriptional activity, which was
dependent on the deacetylase activity of SIRT6. However, the way
in which SIRT6 suppresses cardiomyocyte hypertrophy still needs
to be further clariﬁed. In the present work, we provide the ﬁrst
evidence that SIRT6 ameliorates phenylephrine (PE)-induced car-
diomyocytes hypertrophy partially via regulation of the p300 ace-
tyltransferase and subsequent suppression of NF-kB.
2. Materials and methods
2.1. Primary culture of rat cardiomyocytes
Primary cultures of neonatal rat cardiomyocytes (NRCMs) were
prepared as previously described (16). Cells from the hearts of 1- to
3-day-old SpragueeDawley (SD) rats were cultured in DMEM
supplemented with 10% fetal bovine serum (FBS) and 0.1 mM 5-
bromodeoxyuridine. Before treatment with phenylephrine, the
culture medium was replaced with DMEM containing 1% FBS.
Phenylephrine was dissolved in DMEM to prepare a 100 mM stock
solution. After 16e18 h of serum starvation, phenylephrine was
added to medium (ﬁnal concentration 100 mM) and the cells were
further incubated for indicated time.
2.2. RNA isolation and quantitative RT-PCR (qRT-PCR)
Total RNA from heart tissues or cultured cells was extracted
using Trizol Reagent (Invitrogen, USA) following themanufacturer's
instruction. One microgram of total RNA was reversely transcribed
to ﬁrst strand cDNA using One-step RT kit (Takara Biotechnology,
Dalian, China). The mRNA levels of each targeted genes were
determined by using SYBR-Green Quantitative PCR kit (Takara
Biotechnology) in iCycler iQ system (Bio-Rad, Hercules, CA, USA).
Rat-speciﬁc primers for atrial natriuretic factor (ANF), brain natri-
uretic peptide (BNP), b-myosin heavy chain (b-MHC), p300, SIRT6,
Akt1 and b-actin (listed in Supplementary Material Table S1) were
synthesized by Invitrogen. b-actin served as the endogenous
control.
2.3. Western blot and immunoprecipitation (IP)
Mouse anti-p65 polyclonal antibody (diluted 1:1000), rabbit
anti-acetylated-lysine (Ac-K2-100) monoclonal antibody (diluted
1:1000), mouse anti-ubiquitin monoclonal antibody (diluted1:1000) and rabbit anti-SIRT6 polyclonal antibody (diluted 1:1000)
were purchased from Cell Signaling Technology (Beverly, MA, USA).
Mouse anti-a-tubulin monoclonal antibody (diluted 1:1000) was
from Sigma (St. Louis, MO, USA). Mouse anti-phosphoserine/
threonine/tyrosine monoclonal antibody (diluted 1:200) and
mouse anti-p300 monoclonal antibody (diluted 1:1000) were from
Abcam (Cambridge, MA, USA). Western blot assay was performed
as previously described (17), and a-tubulin served as a loading
control. For co-immunoprecipitation, proteins (800 mg) were
incubated with 1 mg anti-p65 or anti-p300 antibodies for overnight
(mouse normal IgG was used as a control), followed by incubation
for 4 h with protein G-agarose beads (Pierce, Rockford, IL, USA) at
4 C. To detect the changes in phosphorylation and acetylation of
p300, p300 was immunoprecipited from cellular lysates, and then
equal amount of immunoprecipitates were submitted to Western
blot analysis by using anti-phosphoserine/threonine/tyrosine
antibody and anti-acetylated-lysine antibody respectively.
2.4. Measurement of cell surface area
NRCMs grown in 48-well plates were ﬁxed with 4% para-
formaldehyde in phosphate buffer saline (PBS) for 15 min at room
temperature, followed by 0.5% Triton-100 treatment for 5 min.
After incubation with 0.1% rhodamine-phalloidin for 30 min, the
cells were washed with PBS and further incubated with 40,6-
diamidino-2-phenylindole (DAPI). The images were detected by
High Content Screening system (Thermo Fisher Scientiﬁc, Rockford,
IL, USA), and the cell surface area from randomly selected ﬁelds (50
for each group) was determined by a built-in image analysis
software.
2.5. Adenovirus vector
Recombinant adenovirus vectors expressing green ﬂuorescent
protein (Ad-GFP) and GFP-tagged SIRT6 (Ad-SIRT6) respectively
were purchased from Hanbio Technology (Shanghai, China). The
viruses were expanded in HEK293A cells and puriﬁed with a virus
puriﬁcation kit (Biomiga, USA). The puriﬁed viruses were dialyzed
in dilution buffer and stored at 80 C.
2.6. RNA interference
Small interference RNA (siRNA) for SIRT6 (si-SIRT6), p300 (si-
p300) and negative control siRNA (NC) were purchased from
Genepharma (Shanghai, China). The sequences of siRNAs were
shown in Supplementary Material Table S2. NRCMs seeded in
35 mm dishes were transfected with 100 pmol of the indicated
siRNA by using 5 mL lipofectamine 2000 (Invitrogen). Western blot
assay were performed to compare the silencing efﬁciency of
different siRNAs (Supplementary Material Figure S1 and S2).
2.7. Deacetylase activity assay
The deacetylase activity of SIRT6 was determined with a ﬂuo-
rometric assay kit (CycLex, Ina, Nagano, Japan). Proteins (100 mg)
from cardiomyocytes were immunoprecipitated with rabbit anti-
SIRT6 polyclonal antibody. The precipitates (15 mL) were mixed
with a reaction mixture (35 mL) containing 50 mM TriseHCl (pH
8.8), 0.25 mAU$mL1 lysyl-endopeptidase, 1 mM trichostatin A,
800 mM NAD and 20 mM ﬂuorosubstrate peptide, followed by
incubation for 30 min at room temperature. The ﬂuorescence in-
tensity was measured by a microtiter plate ﬂuorometer with exci-
tation at 490 ± 10 nm and emission at 530 ± 10 nm, and normalized
to the protein concentration.
P. Shen et al. / Journal of Pharmacological Sciences 132 (2016) 31e40 332.8. Luciferase reporter gene assay
Dual-luciferase reporter assay system was purchased from
Promega (Madison, WI, USA). The Renilla luciferase vector con-
tained the herpes simplex virus thymidine kinase promoter (pRL-
TK) and NF-kB reporter plasmids pGL4.32. NRCMs were seeded atFig. 1. Overexpression of SIRT6 or knockdown of p300 attenuated PE-induced cardiomyocy
fected with adenovirus encoding SIRT6 (Ad-SIRT6) or control green ﬂuorescent protein (A
submitted to transfection with siRNA targeting SIRT6 (si-SIRT6) or negative control siRNA (N
siRNA interference (si-p300), and the cells were further treated with PE. The hypertrophic re
BNP and b-MHC. Representative images out of three independent experiments were shown
treatment group, #P < 0.05 vs. Ad-GFP plus PE or NC plus PE treatment group, n ¼ 3.5 104 cells/well into 96-well plates, and cotransfected with NF-kB
reporter plasmid (100 ng) and pRL-TK (10 ng) as an internal control.
After 8 h of incubation, the cells were serum-deprived for 12 h and
further subjected to PE stimulation, RNA interference, or trans-
fection with Ad-SIRT6. The cell lysates were prepared with passive
lysis buffer, and then the luciferase activity was measured.te hypertrophy. (A and B) Primary neonatal rat cardiomyocytes (NRCMs) were trans-
d-GFP), and subsequently incubated with 100 mM PE for 24 h (C and D) Cells were
C) followed by PE treatment. (E and F) p300 was knocked down in cardiomyocytes by
sponses were detected by measuring the cell surface area and the mRNA levels of ANF,
, magniﬁcation 400. Data were presented as mean ± SEM. *P < 0.05 vs. Ad-GFP or NC
P. Shen et al. / Journal of Pharmacological Sciences 132 (2016) 31e40342.9. Statistical analysis
Data are presented as mean ± SEM. Statistical analyses between
two groups were performed by unpaired Student's t-test. Differ-
ences among multiple groups were tested by one-way ANOVAwith
Tukey's post hoc test. In all cases, differences were considered sta-
tistically signiﬁcant with P < 0.05.3. Results
3.1. SIRT6 protected cardiomyocytes against hypertrophic responses
induced by phenylephrine
Cultured neonatal rat cardiomyocytes were incubated with
100 mM PE for 24 h. The cardiomyocyte hypertrophy was monitored
by measuring cell surface area and the mRNA levels of ANF, BNP andFig. 2. PE suppressed the protein expression and activity of SIRT6, but increased p300 prote
with deferent concentrations of PE for 24 h. Cells without PE treatment served as control (Co
p300. (C and D) The mRNA expression of p300 was measured by qRT-PCR. (E) The deacetylas
points. Data were presented as mean ± SEM. *P < 0.05 vs. control, n ¼ 3. NS, not signiﬁcanb-MHC, which are well established biomarkers of the hypertrophic
responses. As shown in Fig.1A and B, PE increased the surface area of
cardiomyocytes and elevated the expression of hypertrophy marker
genes. These hypertrophic responses were signiﬁcantly attenuated
by overexpression of SIRT6 with adenovirus vector. In contrast,
transfection of cells with SIRT6 siRNA evoked hypertrophy (Fig. 1C
and D). Moreover, knockdown of p300 by RNA interference also
partially blocked PE-induced hypertrophic responses (Fig. 1E and F).3.2. The changes of SIRT6 and p300 expression in cardiomyocytes
following phenylephrine treatment
To investigate the effects of PE on SIRT6 and p300 expression,
cultured NRCMs were simulated with 100 mM PE for 6, 12 and 24 h,
or with indicated concentrations of PE for 24 h. Then, the cells were
harvested and submitted to Western blot assay. The resultsin level in cardiomyocytes. NRCMs were treated with 100 mM PE for 6, 12 and 24 h, or
n). (A and B) Western blot assay was performed to detect the protein levels of SIRT6 and
e activity of SIRT6 was determined in cells incubated with 100 mM PE for indicated time
t.
P. Shen et al. / Journal of Pharmacological Sciences 132 (2016) 31e40 35revealed that PE decreased the protein expression of SIRT6, but
elevated that of p300, in a time- and concentration-dependent
manner (Fig. 2A and B). However, the data of qRT-PCR showed no
signiﬁcant changes in the mRNA level of p300 following PE treat-
ment (Fig. 2C and D), and PE did not inﬂuence SIRT6 mRNA
expression (Supplementary Material Figure. S3). In addition, the
deacetylase activity of SIRT6 declined gradually with prolonged
incubation time of PE (Fig. 2E).Fig. 3. SIRT6 negatively regulated p300 protein expression, and p300 was involved in t
knockdown of SIRT6 respectively, followed by incubation with or without 100 mM PE for 24 h
double bands detected following SITR6 overexpression represented endogenous SIRT6 and G
qRT-PCR. (E) Cells were transfected with siRNA for SIRT6 (si-SIRT6) alone or together with s
qRT-PCR. Data were presented as mean ± SEM. *P < 0.05 vs. control adenovirus (Ad-GFP) or n
treatment group, #P < 0.05 vs. si-SIRT6 group, n ¼ 3. NS, not signiﬁcant.3.3. SIRT6 modulated p300 protein expression, and p300
participated in the anti-hypertrophic effect of SIRT6
NRCMswere transfected with adenovirus vector encoding SIRT6
cDNA. As shown in Fig. 3A, overexpression of SIRT6 resulted in an
obvious decline in p300 protein level. Moreover, the upregualtion
of p300 protein expression induced by PE was attenuated by SIRT6
overexpression. On the contrary, knockdown of endogenous SIRT6he anti-hypertrophic effect of SIRT6. NRCMs were submitted to overexpression and
(A and B). The protein levels of SIRT6 and p300 were determined by Western blot. The
FP-tagged SIRT6 respectively. (C and D) The mRNA expression of p300 was detected by
iRNA for p300 (si-p300), and then the levels of ANF and BNP mRNA were measured by
egative control siRNA (NC) treatment group, $P < 0.05 vs. Ad-GFP plus PE or NC plus PE
P. Shen et al. / Journal of Pharmacological Sciences 132 (2016) 31e4036
P. Shen et al. / Journal of Pharmacological Sciences 132 (2016) 31e40 37elevated p300 protein expression in cardiomyocytes (Fig. 3B).
Nevertheless, SIRT6 alone or combined with PE treatment did not
inﬂuence themRNA level of p300 (Fig. 3C and D). To further explore
the involvement of p300 in the protective role of SIRT6 against PE-
induced hypertrophy, the cells were concomitantly submitted to
RNA interference for both SIRT6 and p300. The results showed that
depletion of p300 partially inhibited the increase in ANF and BNP
mRNA expression induced by SIRT6 knockdown (Fig. 3E).3.4. SIRT6 promoted proteasome-dependent degradation of p300
via suppressing PI3K/Akt signaling
In NRCMs, no direct interaction between SIRT6 and p300 was
observed with or without SIRT6 overexpresssion (Fig. 4A). To
further elucidate theway bywhich SIRT6modulated p300, the cells
were incubated with the speciﬁc proteasome inhibitor MG132. As
shown in Fig. 4B, MG132 treatment abolished the decrease in p300
protein expression induced by SIRT6 overexpression. Furthermore,
in the presence of MG132, SIRT6 overexpression promoted ubiq-
uitination of p300, indicating the participation of proteasome
degradation pathway in SIRT6-mediated repression of p300
(Supplementary Material Figure S4). Moreover, we found that
overexpression of SIRT6 in cardiomyocytes signiﬁcantly reduced
the protein expression of Akt as well as the phosphorylation at
Thr308 and Ser473, two critical sites for the full activity of Akt
(Fig. 4C). SIRT6 did not affect the acetylation situation of p300.
However, the phosphorylation of p300 was attenuated by SIRT6
overexpression (Fig. 4E). In contrast, SIRT6 RNA interference led to
an increase in the level of phosphorylated p300, which could be
blocked by the treatment with LY294002, a PI3K/Akt pathway in-
hibitor (Fig. 4F and G). These ﬁndings indicated that the negative
modulation of p300 protein expression by SIRT6 might be attrib-
uted to the inhibition of PI3K/Akt pathway.3.5. SIRT6 attenuated the acetylation and transcriptional activity of
NF-kB through inhibiting p300 protein level
Co-immunoprecipitation assay was performed in NRCMs to
identify the direct interaction between p300 and p65, and then the
acetylation situation of p65 was determined. The results showed
that p300 was precipitated by anti-p65 antibody. The binding of
p300 with p65 declined following SIRT6 overexpression, accom-
panying with a decrease in p65 acetylation (Fig. 5A and B). Instead,
knockdown of SIRT6 strengthened the p300/p65 interaction, and
elevated the level of acetylated p65 (Fig. 5C and D). SIRT6 did not
deacetylate p65 directly, since the acetylation situation of p65 in
cells submitted to p300 gene silencing was not inﬂuenced by either
knockdown or overexpression of SIRT6 (Fig. 5E). Furthermore, we
measured the transcriptional activity of NF-kB using luciferase re-
porter assay. As shown in Fig. 5F, knockdown of SIRT6 resulted in an
increase in NF-kB-dependent luciferase activity, which could be
abrogated by p300 depletion. Collectively, these facts indicated the
involvement of p300 in SIRT6-mediated suppression of p65 acet-
ylation and activation.Fig. 4. SIRT6 induced proteasome-dependent degradation of p300 through inhibition of PI3
SIRT6) or siRNA for SIRT6 (si-SIRT6). (A) Co-immunoprecipitation assay was performed to s
protein level of p300 was determined by Western blot in SIRT6-overexpressed cells with or
phosphorylation at Thr308 and Ser473 sites were measured. (E and F) p300 was immuno
detected in equal amount of immunoprecipitates. (G) NRCMs were transfected with si-SIRT6
phosphorylated form were measured after immunoprecipitation. Representative bands from
*P < 0.05 vs. control adenovirus (Ad-GFP) or negative control siRNA (NC) treatment group,4. Discussion
Phenylephrine, a selective a1-adrenergic receptor (a1-AR)
agonist, is widely used as a stimulus for cardiac hypertrophy. Here,
we observed that PE treatment or knockdown of SIRT6 by siRNA
obviously increased the cellular surface area and expression of
hypertrophy marker genes including ANF, BNP and b-MHC in
cultured neonatal rat cardiomyocytes. The hypertrophic responses
induced by PE could be attenuated by SIRT6 overexpression
(Fig. 1AeD). In line with previous reports, these results reinforce
that SIRT6 is a potent negative regulator of cardiac hypertrophy.
Besides this, our data showed that PE or SIRT6 depletion respec-
tively led to cardiomyocyte hypertrophy, but there were no accu-
mulative or synergistic effects between them. This interesting
ﬁnding might be attributed to SIRT6-mediated attenuation of car-
diomyocyte sensitivity to a1-adrenergic stimulation. Extensive
studies have demonstrated that SIRT6 can promote lifespan in an-
imals (18). Deﬁciency of SIRT6 induces cellular senescence, and
SIRT6 knockout mice present multiple phenotypes relevant for
aging (19). Previously, it has been reported that cardiac responses
to a1-AR activation decline with aging (20, 21). Cardiomyocyte Ca2þ
transient induced by PE obvious increases in young rats but drops
in old animals. And PE is not able to activate protein kinase C (PKC)
in senescent rat hearts (22). Since a1-adrenergic stimulation is
tightly associated with intracellular Ca2þ mobilization and PKC
activation, two critical factors in receptor-dependent induction of
myocyte hypertrophy, it raises the possibility that SIRT6 depletion
may block PE-triggered hypertrophic responses via cellular
senescence-induced mechanical dysfunction.
After PE treatment, the protein expression of SIRT6 declined in
cardiomyocytes, while its mRNA level remained intact (Fig. 2A and
B, Supplementary Material Figure S3). In fact, downregulation of
SIRT6 protein expression has been observed during cardiac hy-
pertrophy induced by a variety of hypertrophic stimuli, such as
transverse aortic constriction or chronic infusion of isoproterenol
or angiotensin II (14). As a selective a1-AR agonist, PE is well known
to exert positive inotropic effects in ventricular muscle through the
generation of diacylglycerol and inositol 1,4,5-trisphosphate via
phospholipase C-mediated hydrolysis of phosphatidylinositol 4,5-
bisphosphate, which subsequently leads to PKC activation and
enhanced intracellular Ca2þ release (23). However, besides this
classic a1-adrenergic pathway, accumulating evidence has revealed
that a1-AR activation can also increase cAMP production (24, 25). In
isolated rat cardiomyocytes, a1-AR stimulation by PE activated Gas,
which directly enhanced cAMP synthesis by activating adenylyl
cyclase (26). The cAMP signaling regulates various cellular func-
tions, including metabolism, gene expression, and death (27).
Intriguingly, a recent study shows that cAMP promotes the
ubiquitin-proteasomal degradation of SIRT6 via PKA-dependent
inhibition of the Raf-MEK-ERK pathway (28). Thus, the declined
SIRT6 level following PE treatment might possibly be explained by
increased cAMP-mediated degradation.
Furthermore, the decrease in SIRT6 protein expression following
PE treatment was accompanied by a signiﬁcant drop in the protein
level of p300 (Fig. 2A and B). As a ubiquitous transcriptional coac-
tivator with intrinsic acetyltransferase activity, p300 can acetylate
histones and various transcription factors relating to cellK/Akt signaling. NRCMs were treated with the adenovirus vector expressing SIRT6 (Ad-
how the interaction between p300 and SIRT6 following SIRT6 overexpression. (B) The
without MG132 (10 mM, 12 h) treatment. (C and D) The total protein level of Akt and its
precipitated from cellular lysates. The phosphorylation and acetylation of p300 were
, and further treated with or without LY294002 (20 mM, 20 h). The levels of p300 and its
three independent experiments were shown. Data were presented as mean ± SEM.
#P < 0.05 vs. Ad-SIRT6 or si-SIRT6 group, n ¼ 3.
Fig. 5. SIRT6 inhibited the acetylation and activity of p65 via suppressing p300 protein expression. In NRCMs, SIRT6 was overexpressed by adenovirus-mediated transfection (Ad-
SIRT6), or knocked down by siRNA (si-SIRT6). The cells were further submitted to immunoprecipitation with anti-p65 antibody. (A and B) The binding of p300 with p65 and the
acetylation of p65 were detected respectively by Western blot in cells overexpressing SIRT6. (C and D) The p300/p65 interaction and the level of acetylated p65 were measured
following SIRT6 knockdown. (E) SIRT6 was overexpressed or silenced in NRCMs followed by knockdown of p300. The acetylation of p65 was subsequently determined by
immunoprecipitated. (F) Dual luciferase reporter assay was utilized to evaluate the inﬂuence of SIRT6 knockdown alone or in combination with p300 depletion on NF-kB-dependent
transcriptional activity. Data were presented as mean ± SEM. *P < 0.05 vs. negative control siRNA (NC) treatment group, #P < 0.05 vs. si-SIRT6 group, n ¼ 3.
P. Shen et al. / Journal of Pharmacological Sciences 132 (2016) 31e4038proliferation and survival (29, 30). It is essential for cardiac for-
mation, whereas overexpression of p300 will lead to hypertrophy
and heart failure (31, 32). Our data also showed that genetic
silencing of p300 partly blocked PE-induced cardiomyocyte hy-
pertrophy (Fig.1E and F). Considering SIRT6 and p300 play opposite
roles in the pathogenesis of cardiac hypertrophy, the concurrent
but reverse changes in their protein levels following PE stimulation
indicate that these two molecules may function by affecting each
other. Recently, it has been reported that SIRT1 can deacetylate
lysine residues of p300 leading to its degradation via ubiquitin-
dependent proteasome pathway (33). It intrigued us to investi-
gate whether SIRT6 could also affect the expression of p300.
Indeed, we found that SIRT6 overexpression decreased the protein
level of p300, whereas RNA interference of SIRT6 showed a contrary
inﬂuence (Fig. 3A and B). In addition, knockdown of p300 partially
blocked the upregulation of ANF and BNP mRNA levels induced by
SIRT6 siRNA transfection (Fig. 3E). Together, these results revealthat SIRT6 can negatively regulate p300, which contributes to its
protection against PE-induced hypertrophy.
Most of the biological functions of SIRT6 are ascribed to its
histone deacetylase activity. By deacetylating H3K9 and H3K56,
SIRT6 regulates the expression of genes involved in DNA repair,
telomere maintenance, inﬂammation, as well as metabolism (13).
Here, we found that SIRT6 may not directly regulate p300 expres-
sion through histone deacetylation, since the mRNA level of p300
was intact following overexpression or RNA interference of SIRT6
(Fig. 3C and D). Moreover, the results of co-immunoprecipitation
assay showed no direct interaction between SIRT6 and p300, and
SIRT6 had no inﬂuences on the acetylation of p300 (Fig. 4A, D and
E). These ﬁndings suggest that p300 is not a deacetylation substrate
of SIRT6. In fact, unlike other sirtuin family members such as SIRT1
and SIRT3, whomodulate a diversity of substrates besides histones,
the only reported non-histone protein deacetylated by SIRT6 is C-
terminal binding protein interacting protein (CtIP) (34). To further
Fig. 6. Scheme of the role of SIRT6-mediated p300 degradation in cardiomyocyte
hypertrophy induced by PE. Stimulation of cardiomyocytes with PE decreased SIRT6
protein level and deacetylase activity, leading to elevated Akt expression through
transcriptional regulation. Akt phosphorylated p300 and thereby suppressed its
ubiquitin-proteasomal degradation. Subsequently, p300 acetylated NF-kB subunit p65,
which resulted in enhanced transcriptional activity of p65 and then triggered hyper-
trophic responses.
P. Shen et al. / Journal of Pharmacological Sciences 132 (2016) 31e40 39investigate the mechanism underlying SIRT6-mediated decline in
p300 protein expression, cardiomyocytes were transfected with
adenovirus vector expressing SIRT6 and simultaneously incubated
with MG132, a widely used potent proteasome inhibitor. The
presence of MG132 signiﬁcantly blocked the decrease in p300
protein level after SIRT6 overexpression (Fig. 4B). Besides, the
ubiquitination of p300 increased after transfected with Ad-SIRT6,
showing the involvement of proteasome degradation pathway in
the modulation of p300 by SIRT6.
It has been proven that ubiquitination of p300 is associated with
unphosphorylated form, and dephosphorylation of p300 by phos-
phatase can serve as a signal to designate it for proteolysis (35). In
contrast, phosphorylation of p300 by protein kinases plays an
important role in maintaining transcriptional activity as well as the
metabolic stability of this co-activator. To date, multiple signaling
pathways have been identiﬁed in the regulation of p300 protein
turnover. Akt is known to phosphorylate p300 at Ser1834 to inhibit
its ubiquitination, and the activity of Akt is required for the steady-
state level of p300 (36). Inhibition on PI3K/Akt pathway will pro-
mote the ubiquitination of p300 and its degradation through the
26S proteasome pathway (37). SIRT6 transcriptionally represses
Akt signaling at the level of chromatin. SIRT6 forms a complex with
c-Jun and deacetylates H3K9, which results in the condensation of
chromatin and the suppression of the IGF/Akt pathway-related
genes expression (14). Thus, it may be possible that SIRT6-
induced increase in p300 protein ubiquitination and degradation
is associated with inhibition of Akt signaling. As shown in Fig. 4C
and E, SIRT6 overexpression reduced the protein level of Akt and its
phosphorylation at Thr308 and Ser473, both of which contribute to
its full activity. And Akt mRNA level was decreased by SIRT6 over-
expression (Supplementary Material Figure S5). Moreover, the level
of phosphorylated p300 declined progressively with time after
SIRT6 overexpression, while the ubiquitination of p300 increased
correspondingly (Supplementary Material Figure S6), indicating
that the phosphorylation of p300 was accompanied with its
ubiquitin-proteasomal degradation. In contrast, genetic silencing of
SIRT6 signiﬁcantly elevated Akt protein expression and the level of
phosphorylated p300 (Fig. 4D and F). The PI3K/Akt pathway in-
hibitor LY294002 reversed the increase in the phosphorylation of
p300 induced by SIRT6 siRNA transfection (Fig. 4G). Convergently,
these ﬁndings suggest that SIRT6 attenuates p300 phosphorylation
through suppression of Akt signaling, which may subsequently
facilitate the ubiquitin-proteasomal degradation of p300.
Our previous study has indicated that SIRT6 interacts directly
with p65 in cardiomyocytes, and thereby protects cardiomyocytes
from hypertrophy via inhibiting NF-kB activation (16). As an
important transcription factor, NF-kB has beenwell demonstrated to
trigger cardiac hypertrophy (38e41). Through physical association
with p65, SIRT6 is recruited to chromatin at the promoters of p65
target genes, where it represses p65-dependent gene expression by
deacetylating H3K9 (14). In this study, we found that SIRT6 could
also downregulate p300 protein level in cardiomyocytes. p300
acetylates the p65 subunit of NF-kB at Lys310, a modiﬁcation that
enhances the DNA binding ability of p65 and is required for its full
transcriptional activity (42). Therefore, we supposed that SIRT6-
mediated inhibition on p300 protein expression would subse-
quently affect the acetylation and function of p65, contributing to the
protection against hypertrophy. Here, our results showed that after
overexpression of SIRT6, the combination of p300 and p65 was
signiﬁcantly decreased. In contrast, SIRT6 depletion enhanced p300/
p65 interaction (Fig. 5A and C). Moreover, SIRT6 negatively inﬂu-
enced the acetylation level of p65 (Fig. 5B and D). And when p300
was knocked down, the increase in p65 acetylation and transcrip-
tional activity following SIRT6 siRNA transfection was dramatically
inhibited (Fig. 5E and F). These results suggest that SIRT6 cansuppress p65 activation throughmodulating p300. Certainly, further
studies are required to conﬁrm and elucidate this possible mecha-
nism especially by using in vivo models.
In summary, the present study reveals that p300 is involved in
the protective effect of SIRT6 against PE-induced cardiomyocyte
hypertrophy. SIRT6 reduces p300 protein level via promoting its
degradation, which can be attributed to the suppression of Akt
signaling. And it subsequently leads to signiﬁcant decrease in the
acetylation and activation of NF-kB subunit p65 (Fig. 6). These
ﬁndings give a further insight into the mechanism underlying the
anti-hypertrophic role of SIRT6 and support the potential of SIRT6
as a therapeutic target for cardiac hypertrophy.
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